Global Analgesics Market to Reach $59.2 Billion by 2026

SAN FRANCISCO, March 16, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Analgesics - Global Market Trajectory & Analytics". The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace.

FACTS AT A GLANCE

What's New for 2022?

• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to our digital archives and MarketGlass Research Platform
• Complimentary updates for one year

Edition: 20; Released: February 2022

Executive Pool: 9928
Companies: 146 - Players covered include Amneal Pharmaceuticals Inc; Apotex Inc; AstraZeneca Plc; Aurobindo Pharma Limited; Bausch Health Companies Inc.; Bayer AG; Cipla Limited; Eli Lilly and Company; Endo International plc; F. Hoffmann-La Roche AG; Fresenius Kabi AG; GlaxoSmithKline PLC; Hikma Pharmaceuticals PLC; Iroko Pharmaceuticals, LLC; Johnson & Johnson; Lupin Limited; Novartis AG; Reckitt Benckiser Group plc; Sanofi S.A.; Sun Pharmaceutical Industries Ltd; Teva Pharmaceutical Industries Ltd and Others.
Coverage: All major geographies and key segments
Segments: Drug Type (Prescription, OTC); Drug Class (Opioids, NSAIDs, Other Drug Classes); Route of Administration (Oral, Parenteral, Topical, Transdermal, Rectal)
Geographies: World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Complimentary Project Preview - This is an ongoing global program. Preview our research program before you make a purchase decision. We are offering a complimentary access to qualified executives driving strategy, business development, sales & marketing, and product management roles at featured companies. Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more. You may also build your own bespoke report using our MarketGlass™ Platform which offers thousands of data bytes without an obligation to purchase our report. Preview Registry

ABSTRACT-

Global Analgesics Market to Reach $59.2 Billion by 2026
Pain management continues to be one of the most sought-after treatment options for patients within the healthcare arena that underscores the critical significance of analgesics. Analgesics are drugs meant for pain control primarily. The drugs work on the CNS and peripheral nervous system for reducing or blocking pain sensitivity. There are also analgesics which work by preventing creation of pain mediating chemicals in the body. Widely used for treatment of mild to acute pain attributed to several medical conditions, injuries, surgeries and terminal disorders, analgesics have ruled the pain management domain for the past several decades. These medications have provided medical practitioners with an effective option to alleviate pain and help improve quality of life for patients. One of the important growth factors for the market for analgesics worldwide is the aging population. Significant incidence of severe pain disorders, treatment options that are effective, and favorable regulations are the key driving forces of the market. Further, increasing prevalence of chronic diseases has also fostered the use of pain management therapeutics. Increasing innovation in the area, owing to increased research investment by drug development companies, for advancing combination of compounds for developing new and more effective analgesics with enhanced efficacy as well as fewer side effects, is another prominent factor contributing towards market growth.

Amid the COVID-19 crisis, the global market for Analgesics estimated at US$48.8 Billion in the year 2022, is projected to reach a revised size of US$59.2 Billion by 2026, growing at a CAGR of 4.7% over the analysis period. Prescription, one of the segments analyzed in the report, is projected to grow at a 4.4% CAGR to reach US$37.7 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the OTC segment is readjusted to a revised 5.1% CAGR for the next 7-year period. This segment currently accounts for a 38.2% share of the global Analgesics market.

The U.S. Market is Estimated at $15.9 Billion in 2022, While China is Forecast to Reach $8.2 Billion by 2026
The Analgesics market in the U.S. is estimated at US$15.9 Billion in the year 2022. The country currently accounts for a 32.76% share in the global market. China, the world's second largest economy, is forecast to reach an estimated market size of US$8.2 Billion in the year 2026 trailing a CAGR of 6.5% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.3% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR while Rest of European market (as defined in the study) will reach US$8.8 Billion by the close of the analysis period.

Growth in these markets are benefiting from increasing incidence of diseases like cancer, arthritis, CVD, and also other acute and chronic diseases which causes severe pain. Cancer pain, neuropathic pain, post-operative pain, and lower back pain represent the important market segments. Increasing incidence of cancer globally is poised to be a key driving force for market growth. Further, increasing prevalence of chronic diseases has also fostered the use of pain management therapeutics. Increasing innovation in the area, owing to increased research investment by drug development companies, for advancing combination of compounds for developing new and more effective analgesics with enhanced efficacy as well as fewer side effects, is another prominent factor contributing towards market growth.

Opioids Segment to Reach $18.4 Billion by 2026
Opioid analgesic drugs represent the gold standard in pain relieving treatment of critically ill patients across disease segments, including COVID-19. Fentanyl, morphine, and hydromorphone are among the most commonly used IV opioid analgesic drugs in the ICU settings for COVID as well as non-COVID patients. Global Opioids segment is estimated at US$15.9 Billion in 2022, and is projected to reach US$18.4 Billion by 2026 reflecting a compounded annual growth rate of 3.7% over the analysis period. United States constitutes the largest regional market for Opioids segment, accounting for 29.9% of the global sales. China is poised to register the fastest compounded annual growth rate of 5.2% over the analysis period, to reach US$2.6 Billion by 2026. More

MarketGlass™ Platform
Our MarketGlass™ Platform is a free full-stack knowledge center that is custom configurable to today`s busy business executive`s intelligence needs! This influencer driven interactive research platform is at the core of our primary research engagements and draws from unique perspectives of participating executives worldwide. Features include - enterprise-wide peer-to-peer collaborations; research program previews relevant to your company; 3.4 million domain expert profiles; competitive company profiles; interactive research modules; bespoke report generation; monitor market trends; competitive brands; create & publish blogs & podcasts using our primary and secondary content; track domain events worldwide; and much more. Client companies will have complete insider access to the project data stacks. Currently in use by 67,000+ domain experts worldwide.

Our platform is free for qualified executives and is accessible from our website www.StrategyR.com or via our just released mobile application on iOS or Android

About Global Industry Analysts, Inc. & StrategyR™
Global Industry Analysts, Inc., (www.strategyr.com) is a renowned market research publisher the world`s only influencer driven market research company. Proudly serving more than 42,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for over 33 years.

CONTACTS:
Zak Ali
Director, Corporate Communications
Global Industry Analysts, Inc.
Phone: 1-408-528-9966
www.StrategyR.com
Email: [email protected]

LINKS
Join Our Expert Panel
https://www.strategyr.com/Panelist.asp

Connect With Us on LinkedIn
https://www.linkedin.com/company/global-industry-analysts-inc./

Follow Us on Twitter
https://twitter.com/marketbytes

Journalists & Media
[email protected]

SOURCE Global Industry Analysts, Inc.